Ricevi le ultime notizie sulle azioni Agenus con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di AGEN

Ultime notizie per

AGENUS INC

Agenus

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus Inc

Agent Information Software Inc Com

Agentix Corp

Press Releases

Agenus Announces Virtual Annual Shareholders Meeting

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation

Small Cap

Opinion

From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

AGEN

AVAI

CELC

CLOV

EVAX

LYEL

MGRM

ONCY

TREN

TSX:ONC

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Compugen

Coherus Oncology

Climb Bio

Cardiff Oncology

Citius Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Fate Therapeutics

Forte Biosciences

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Seres Therapeutics

MEI Pharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Theratechnologies

Baird

HC Wainwright & Co.

B. Riley Securities

Jefferies

EF Hutton

Comments

Agenus Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO